StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Analysts at StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report issued on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Down 16.5 %

Shares of NASDAQ BCLI opened at $0.76 on Friday. Brainstorm Cell Therapeutics has a twelve month low of $0.75 and a twelve month high of $10.05. The business has a fifty day simple moving average of $1.50 and a two-hundred day simple moving average of $1.80. The firm has a market cap of $4.97 million, a PE ratio of -0.16 and a beta of 0.60.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.